Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Ovarian Cancer · Breast Cancer · Pancreatic Cancer · Prostate Cancer · Additional Indications Below for Module 4 and 5 · Non-small Cell Lung Cancer · Colorectal Cancer · Bladder Cancer · Gastric Cancer · Biliary Cancer · Cervical Cancer · Endometrial Cancer · Small Cell Lung Cancer Only in Module 5
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 702 (final count)
- Started
- Nov 12, 2020
- Main results expected
- May 28, 2027
- Fully finished
- May 28, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
The number of subjects with adverse events/serious adverse events
Measured over: From time of Informed Consent to 28 + 7 days post last dose ( modules 1,2,3,5 and 6). 40+7 days post last dose for Module 4.
The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.
Measured over: From first dose of study treatment until the end of Cycle 1.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04644068 · record last updated 2026-09-21 · checked 2026-11-09 15:47 UTC